{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:52:38Z","timestamp":1785541958249,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.dld.2007.09.001","type":"journal-article","created":{"date-parts":[[2007,11,26]],"date-time":"2007-11-26T15:24:26Z","timestamp":1196090666000},"page":"1043-1051","source":"Crossref","is-referenced-by-count":74,"title":["NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: What lies beyond the horizon"],"prefix":"10.1016","volume":"39","author":[{"given":"S.","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2007.09.001_bib1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2007.09.001_bib2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrd1225","article-title":"COX-2 and beyond: approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dld.2007.09.001_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2007.09.001_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1096\/fasebj.10.7.8635690","article-title":"The cellular and molecular basis of gastric mucosal defense","volume":"10","author":"Wallace","year":"1996","journal-title":"FASEB J"},{"key":"10.1016\/j.dld.2007.09.001_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.dld.2007.04.002","article-title":"Coxibs and non-selective NSAIDs in the gtsrointestinal setting: what should patients and physicians do","volume":"39","author":"Lazzaroni","year":"2007","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.dld.2007.09.001_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2007.09.001_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2007.09.001_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2007.09.001_bib9","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S1590-8658(03)00047-1","article-title":"NO-aspirin: mechanism of action and gastrointestinal safety","volume":"35","author":"Fiorucci","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2007.09.001_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrd794","article-title":"Potential cardioprotective actions of nitric oxide-releasing aspirin","volume":"1","author":"Wallace","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dld.2007.09.001_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/187152806776383161","article-title":"NO-NSAIDs: from inflammatory mediators to clinical readouts","volume":"5","author":"Fiorucci","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.dld.2007.09.001_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2006.11.042","article-title":"Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat","volume":"132","author":"Wallace","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.freeradbiomed.2006.12.011","article-title":"Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative","volume":"42","author":"Li","year":"2007","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.dld.2007.09.001_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.gastro.2006.02.033","article-title":"The emerging roles of hydrogen sulphide in the gastrointestinal tract and liver","volume":"131","author":"Fiorucci","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib15","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1053\/gast.2002.36558","article-title":"Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage","volume":"123","author":"Fiorucci","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2007.09.001_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2007.09.001_bib18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2007.09.001_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2007.09.001_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2007.09.001_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2007.09.001_bib22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study","volume":"165","author":"Johnsen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.dld.2007.09.001_bib23","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis","volume":"364","author":"Juni","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2007.09.001_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0165-6147(03)00166-4","article-title":"A magic bullet for mucosal protection \u2026 and aspirin is the trigger!","volume":"24","author":"Wallace","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.dld.2007.09.001_bib25","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1096\/fj.02-0777fje","article-title":"Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin","volume":"17","author":"Fiorucci","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.dld.2007.09.001_bib26","doi-asserted-by":"crossref","first-page":"10937","DOI":"10.1073\/pnas.1933204100","article-title":"Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa","volume":"100","author":"Fiorucci","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dld.2007.09.001_bib27","first-page":"G462","article-title":"Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process","volume":"259","author":"Wallace","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.dld.2007.09.001_bib28","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/0016-5085(91)90259-N","article-title":"A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit","volume":"100","author":"Wallace","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0016-5085(95)90065-9","article-title":"Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats","volume":"108","author":"Santucci","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-2999(94)90136-8","article-title":"A diclofenac derivative without ulcerogenic properties","volume":"257","author":"Wallace","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dld.2007.09.001_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0016-5085(94)90074-4","article-title":"Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat","volume":"107","author":"Wallace","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/156802607779941350","article-title":"Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a reviewof their current status","volume":"7","author":"Stefano","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.dld.2007.09.001_bib33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1124\/jpet.104.072843","volume":"311","author":"Fiorucci","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dld.2007.09.001_bib34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0016-5085(99)70012-0","article-title":"Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats","volume":"116","author":"Fiorucci","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/gast.2003.50096","article-title":"Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study","volume":"124","author":"Fiorucci","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2007.09.001_bib36","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4049\/jimmunol.173.2.874","article-title":"Nitric oxide regulates immune cell bioenergetic: a mechanism to understandimmunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs","volume":"173","author":"Fiorucci","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.dld.2007.09.001_bib37","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/gut.52.11.1537","article-title":"Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.dld.2007.09.001_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/ard.2004.023572","article-title":"STAR Multinational Study Group","volume":"64","author":"Lohmander","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2007.09.001_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clpt.2005.01.011","article-title":"Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake","volume":"77","author":"Huledal","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2007.09.001_bib40","doi-asserted-by":"crossref","unstructured":"Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen. Drugs R D 2006; 7(4):262\u20136.","DOI":"10.2165\/00126839-200607040-00007"},{"key":"10.1016\/j.dld.2007.09.001_bib41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/art.21586","article-title":"Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee","volume":"53","author":"Schnitzer","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dld.2007.09.001_bib42","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1096\/fj.02-0211hyp","article-title":"Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?","volume":"16","author":"Wang","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.dld.2007.09.001_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1124\/jpet.105.091595","article-title":"Evidence that hydrogen sulphide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels","volume":"316","author":"Distrutti","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dld.2007.09.001_bib44","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1096\/fj.06-7407com","article-title":"Sulfide, the first inorganic substrate for human cells","volume":"21","author":"Goubern","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.dld.2007.09.001_bib45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.106.106435","article-title":"5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulphide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity","volume":"319","author":"Distrutti","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dld.2007.09.001_bib46","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1096\/fj.06-6270fje","article-title":"Hydrogen sulphide is an endogenous modulator of leukocyte-mediated inflammation","volume":"20","author":"Zanardo","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.dld.2007.09.001_bib47","first-page":"19","article-title":"Evidence for a new mechanism of action of diclofenac: activation of K+ channels","volume":"44","author":"Ortiz","year":"2001","journal-title":"Proc West Pharmacol Soc"},{"key":"10.1016\/j.dld.2007.09.001_bib48","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjp.0707193","article-title":"Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis","volume":"150","author":"Fiorucci","year":"2007","journal-title":"Br J Pharmacol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865807005361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865807005361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,5]],"date-time":"2019-05-05T03:28:07Z","timestamp":1557026887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865807005361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1590865807005361"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2007.09.001","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}